US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

38.96

-0.2700-0.69%

Post-market: 39.230.2700+0.69%16:10 EDT

Volume:279

Turnover:10.81K

Market Cap:7.79M

PE:- -

High:38.96

Open:39.22

Low:38.96

Close:39.23

52wk High:43.01

52wk Low:24.96

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.12

T/O Rate:0.14%

Dividend:0.32

Dividend Rate:0.83%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Scholar Rock Drops Catalent Indiana from Apitegromab BLA After FDA Flags Site Inspection as OAI

Scholar Rock Holding Corporation - to Remove Catalent Indiana Facility from Apitegromab Bla

THOMSON REUTERS

Scholar Rock Holding Corporation - Engaging with Ema to Include Second Fill-Finish Facility in Apitegromab Maa

THOMSON REUTERS

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch Immediately upon FDA Approval

THOMSON REUTERS

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (Bla) for Spinal Muscular Atrophy (Sma) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), Scholar Rock Holding (SRRK) and Ascendis Pharma (ASND)

Grail announces FDA advisory committee meeting to review Galleri test PMA

Praxis Precision Med is Maintained at Equal-Weight by Wells Fargo

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)

Praxis Precision price target raised to $514 from $400 at Baird

Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $475 from $374

THOMSON REUTERS

Scholar Rock Holding Corporation : Bmo Raises Target Price to $76 from $70

THOMSON REUTERS

Hong Kong Stocks Update | INSILICO Surges Over 9% as ISM8969/HT-001 Receives NMPA Clinical Trial Approval for Parkinson's Disease Treatment

Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26

Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IBRN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":38.9601,"timestamp":1788206400000,"preClose":39.2301,"halted":0,"volume":279,"hourTrading":{"tag":"盘后","latestPrice":39.2301,"preClose":38.9601,"latestTime":"16:10 EDT","volume":7,"amount":272.7207,"timestamp":1788207004390,"change":0.27,"changeRate":0.00693,"amplitude":0},"delay":0,"changeRate":-0.006882470348023664,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.27,"latestTime":"08-31 16:00:00 EDT","open":39.22,"high":38.9601,"low":38.9601,"amount":10811,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":39.2301,"sharesOutstanding":150000,"nav":39.171708,"aum":7834341.6,"dividendRate":0.008257,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.2301,"preClose":38.9601,"latestTime":"16:10 EDT","volume":7,"amount":272.7207,"timestamp":1788207004390,"change":0.27,"changeRate":0.00693,"amplitude":0},"volumeRatio":0.121537,"impliedVol":0.124,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.121537,"shares":200000,"dividePrice":0.3217,"high":38.9601,"amplitude":0,"preClose":39.2301,"low":38.9601,"week52Low":24.9594,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":38.9601,"eps":0,"divideRate":0.008257,"volume":279,"delay":0,"ttmEps":0,"open":39.22,"prevYearClose":32.3193,"prevWeekClose":39.2301,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":39.5297,"twentyDayClose":36.6969,"sixtyDayClose":34.9273},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657673626","title":"Scholar Rock Drops Catalent Indiana from Apitegromab BLA After FDA Flags Site Inspection as OAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2657673626","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657673626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134089,"startTime":"0","endTime":"0","summary":"Scholar Rock drops Catalent Indiana from apitegromab BLA after FDA flags site inspection as OAIScholar Rock’s FDA review of the apitegromab BLA for spinal muscular atrophy will proceed with only its s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLbzqzQq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626616","title":"Scholar Rock Holding Corporation - to Remove Catalent Indiana Facility from Apitegromab Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626616?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619626","title":"Scholar Rock Holding Corporation - Engaging with Ema to Include Second Fill-Finish Facility in Apitegromab Maa","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","IBRN","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657266176","title":"Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch Immediately upon FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657266176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657266176?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657162661","title":"Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (Bla) for Spinal Muscular Atrophy (Sma) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2657162661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657162661?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623471","title":"Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623471?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:00","pubTimestamp":1786129228,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oculis Holding (OCS) and Xenon (XENE) with bullish s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","OCS","XENE","BK4139","BK4007","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628087","title":"Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628087","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628087?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:02","pubTimestamp":1786125732,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals'  recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","SBIO","BK4585","BK4139","IBRN","XENE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628511","title":"Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), Scholar Rock Holding (SRRK) and Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628511?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:10","pubTimestamp":1786122610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Progyny (PGNY), Scholar Rock Holding (SRRK) and Asce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-progyny-pgny-scholar-rock-holding-srrk-and-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-progyny-pgny-scholar-rock-holding-srrk-and-ascendis-pharma-asnd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU1878469433.USD","IBRN","BK4154","BK4581","PGNY","HCSG","LU0029874061.USD","BK4137","XLV","SRRK","XBI","BK4585","LU0128526141.USD","BK4588","THNR","MEDI","LU0889565916.HKD","ASND","BK4139","LABU","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642727","title":"Grail announces FDA advisory committee meeting to review Galleri test PMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642727","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642727?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:10","pubTimestamp":1786115445,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IBRN","PMA","GRAL","BK4588","XBIX","BBH","SBIO","BK4129","PBE","BBP","BK4139","FBT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641228","title":"Praxis Precision Med is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641228","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641228?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:07","pubTimestamp":1786111620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU0128525689.USD","LU0889565916.HKD","TFNS","LU2461242641.AUD","IE00BJT1NW94.SGD","LU0310800965.SGD","KBWB","BK4504","LU0162691827.USD","BK4585","IE0002141913.USD","BK4139","LU2236285917.USD","LU1280957306.USD","LU1506573853.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0251142724.SGD","IE00BFTCPJ56.SGD","LU0971096721.USD","IYF","IBRN","LU0868494617.USD","BK4207","FTXO","LU0211327993.USD","LU0640476718.USD","LU1201861249.SGD","IE0009355771.USD","LU0211328371.USD","BK4582","LU1814569148.SGD","IE0002270589.USD","LU0320765489.SGD","PRAX","PGF","LU2361044949.HKD","LU0072461881.USD","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU0868494708.USD","LU0742534661.SGD","LU0048573561.USD","LU1894683264.USD","LU0256863811.USD","LU1074936037.SGD","LU1267930227.SGD","BK4559","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645754","title":"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645754?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:40","pubTimestamp":1786106428,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS), Immunocore Holdings (IMCR) and Pra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4505","LU0889565916.HKD","BK4007","LU0109394709.USD","IE0009355771.USD","IBRN","IE00BFTCPJ56.SGD","LABU","LU0029874061.USD","IE0002141913.USD","VTRS","IMCR","IE00B2B36J28.USD","LU0128526141.USD","BK4583","BK4581","LU0320765992.SGD","XBI","LU1839511570.USD","BK4585","IE00BJT1NW94.SGD","PRAX","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2087621335.USD","BK4588","XLV","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643664","title":"Praxis Precision price target raised to $514 from $400 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:01","pubTimestamp":1786104075,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Praxis Precision (PRAX) to $514 from $400 and keeps an Outperform rating on the shares. The firm updated it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IBRN","BK4139","LU0109394709.USD","IE00BJT1NW94.SGD","PRAX","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009355771.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648808","title":"Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $475 from $374","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648808?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:26","pubTimestamp":1786101999,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44419L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4139","IE0002141913.USD","IBRN","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","PRAX","IE00B2B36J28.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610982","title":"Scholar Rock Holding Corporation : Bmo Raises Target Price to $76 from $70","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610982?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:08","pubTimestamp":1786100892,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN444123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136673857","title":"Hong Kong Stocks Update | INSILICO Surges Over 9% as ISM8969/HT-001 Receives NMPA Clinical Trial Approval for Parkinson's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1136673857","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136673857?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:10","pubTimestamp":1786083017,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) surged more than 9%, trading up 8.1% at HK$44.3 as of the latest update, with a turnover of HK$541 million.According to recent news from Insilico's official WeChat account,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1612","BK4585","BMED","BK4588","MDTX","01611","BK1141","BK1167","IBBJ","IBRN","KCAI","VXUS","BK4218","HT","03696","PSYK","BK4181","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657080663","title":"Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657080663","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657080663?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050101,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings SummaryXenon Pharmaceuticals Inc.XENE.OQreported a quarterly adjusted loss of $1.11 per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650957","title":"Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650957?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047436,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q2 net loss widens on higher warrant costsOverviewUS biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expensesCompany raised $805 mln in public offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","DTIL","LU0109394709.USD","LU0889565916.HKD","VTVT","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","DFTX","IE0009355771.USD","LU0320765992.SGD","IBRN","BK4007","IE0002141913.USD","IE00B4R5TH58.HKD","PRAX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2324357040.USD","IBRN","NBIX","IE00B4R5TH58.HKD","PRAX","LU2065170008.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","PSIL","LU2065171402.SGD","LU0154245673.USD","SBIO","IE00BJT1NW94.SGD","BK4139","BK4563","LU0889565916.HKD","LU0823416689.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0154245756.USD","XENE","GHRS","IMRX","LU2065169927.USD","BK4539","IE0009355771.USD","BK4007","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4139","SG9999014013.SGD","IBRN","LU2095319765.USD","BK4585","BCDF","SG9999014021.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","XENE","IE00BKPKM429.USD","LU2210149790.SGD","SBIO","IE00BN0W2T93.GBP","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}